Google's VP of search products and user experience shares the rules that gives the search company its innovative edge. (Interesting talk with @marrisamayer: 9 timeless principles of #innovation via @fastcompany.
Design firm Demner, Merlicek & Bergmann has replaced the traditional label on bottles of Stiegl beer with a free public transportation ticket in an effort to curb drink driving. (@janewells interesting drinking innovation ...
Five ingredients for innovation Washington Post (blog) The political, social, and economic problems of tomorrow aren't going to be solved using the methods honed by Baby Boomers and their parents (no offense to either generation).
Professor György K.B. Sándor believes that tissue engineering can become a new global export item. Sándor specializes in oral and maxillofacial surgery, and does research on bone regeneration, hyperbaric oxygen therapy, ...
Tissue-engineered heart valve (credit: HIA/Wikimedia Commons) Professor György K.B. Sándor believes that tissue engineering can become a new global export
Professor György K.B. Sándor believes that tissue engineering can become a new global export item.
Sándor specializes in oral and maxillofacial surgery, and does research on bone regeneration, hyperbaric oxygen therapy, tissue engineering, and stem cells.
The goal of his research at the University of Tampere in Finland is to produce bone and cartilage using tissue engineering and to optimize the use of tissue-derived stem cells for bone defects.
With tissue engineering, it is possible to produce tailored, living human spare parts. If the method can be rolled out on a larger scale, it may become the third alternative form of treatment alongside the traditional forms, surgery and pharmacotherapy.
“Tissue-derived stem cells can be isolated from the patient’s own tissue. In that way, they will not cause a rejection reaction. Compared to tissue stem cells, human embryonic stem cells have a greater ability to differentiate into different cell types. In practice, it means that all cell types can be used,” Sándor says.
“At the moment, expertise in the field is concentrated in Finland, but it has also generated global interest in other medically advanced countries,” says Sándor.
In the near future, it is possible that larger numbers of patients will travel to Finland to receive treatment. Sándor believes that as forms of treatment develop, expertise can also be exported abroad to be used on a larger scale.
Sándor works at the BioMediTech research institute run by the University of Tampere and the Tampere University of Technology. BioMediTech is an innovation center that combines biomedicine and technology.
“We have proven with more than 20 clinically successful operations that tissue engineering works,” Sándor says.
FiDiPro (The Finland Distinguished Professor Programme) is a joint funding program of the Academy of Finland and Tekes. FiDiPro enables top researchers, both international and expatriates, to work in Finland for a fixed period of time.
In a huge victory for ALS sufferers, FDA granted Genervon Biopharmaceuticals a fast track designation for its first in class highly effective multi-target master regulator biotechnology drug GM604 for ALS.
This report from the European Academies Science Advisory Council EASAC explores some of the issues associated with the genetic modification of crops, where the EU has fallen behind in its adoption of the technology, compared with many other regions of the world. Concerns have been expressed that a timeconsuming and expensive regulatory framework in the EU, compounded by politicisation of decision-making by Member States and coupled with other policy inconsistencies, has tended to act as an impediment to agricultural innovation. Controversies about the impact of genetically modified (GM) crops have too often been based on contested science or have confounded effects of the technology with the impact of agriculture per se or changes in agronomic practice. The report concludes that it is vital to address the policy disconnects because there is a wide range of opportunities in prospect for improving agricultural productivity and efficiency, environmental quality and human health, by using all available technologies where appropriate.
Putin Pledges to Support Perinatal Medicine RIA Novosti MOSCOW, June 23 (RIA Novosti) - The Russian authorities will support perinatal medicine, develop neonatal surgery and build perinatal centers, President Vladimir Putin said at the XI World...
How can companies ensure that a promising initiative receives the necessary resources? And why do so many brilliant inventions fail while other seemingly mediocre offerings succeed? Such questions are addressed in two recent books — Unrelenting Innovation: How to Build a Culture for Market Dominance, by Gerard J. Tellis and The Wide Lens: A New Strategy for Innovation, by Ron Adner. The first book concentrates on a company’s internal workings, while the latter focuses on its external environment.
In Unrelenting Innovation, Tellis asserts that the single most important driver of innovation in any organization is its culture, and he cites three organizational traits important for innovation: a willingness to cannibalize existing products, a risk-taking attitude and the ability to focus on the future. Many companies have a hard time commercializing radical innovations, Tellis notes, because these would hurt the company’s existing products. To counter such tendencies, Tellis offers three practices: providing the right incentives, fostering internal markets and empowering “innovation champions” within the organization.